Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
DNA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Ginkgo Bioworks Holdings, Inc.NYSE: DNA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $37.83M fell 22.9% year over year, ahead of the -23.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 17.8% from the prior quarter. Over 3 fiscal years it compounded at -49.6% a year.
Context
- Selling, general & admin amounted to 107.7% of revenue in FY2025, down 0.7 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $169.96M (-7.3%) for the fiscal year ending Dec 2026, a step up from the -25.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $37.83M-17.8% QoQ
- Last fiscal yearDec 2025
- $183.29M-25.5% YoY
- LTMMar 2026
- $172.08M-23.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 183.29M USD
- Year-over-year change
- -25.5%
- 4-year CAGR
- -32.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 183.29M | -25.5% |
| FY2024 | 2024-12-31 | 246.16M | -36.1% |
| FY2023 | 2023-12-31 | 385.03M | -73.1% |
| FY2022 | 2022-12-31 | 1.43B | +65.7% |
| FY2021 | 2021-12-31 | 862.95M | — |
Selling, General & Admin vs competitors
How DNA compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -23.5% is the 7th highest of 8, against a peer median of -3.3%.
- Selling, general & admin amounts to 121.8% of revenue for DNA, versus a peer median of 69.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.08M USD | -23.5% | -49.6% | 121.8% | |
| LTM Sep 2026 | $153.2M USD | -3.3% | +13.5% | 40.4% | |
| LTM Jun 2026 | $152.74M USD | -3.6% | +9.9% | 73.2% | |
| LTM Mar 2026 | $86.5M USD | -47.9% | +3.9% | 96.8% | |
| LTM Mar 2026 | €70.46M EUR | -23.0% | +9.1% | 45.1% | |
| LTM Dec 2025 | $69.65M USD | — | — | — | |
| LTM Mar 2026 | $69.19M USD | — | — | 105.6% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $59.07M USD | +263.5% | +71.2% | — |
| LTM Mar 2026 | $52.46M USD | -2.3% | +4.4% | 65.8% | |
| LTM Mar 2026 | $27.19M USD | +59.1% | +55.2% | — | |
| Peer median (excluding DNA) | — | -3.3% | +9.9% | 69.5% | |
Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 313.84M | 477.71M | 251.46M | 227.04M | 170.16M |
| Cost of Revenue | 129.69M | 204.22M | 54.01M | 38.55M | 31.52M |
| Gross Profit | 184.15M | 273.49M | 197.45M | 188.49M | 138.63M |
| Gross Margin | 58.7% | 57.3% | 78.5% | 83.0% | 81.5% |
| Research & Development | 1.15B | 1.05B | 580.62M | 424.06M | 243.77M |
| Selling, General & Admin | 862.95M | 1.43B | 385.03M | 246.16M | 183.29M |
| Operating Expenses | 2.01B | 2.48B | 1.06B | 748.25M | 453.91M |
| Depreciation & Amortization | 29.08M | 61.63M | 71.55M | 63.02M | 58.99M |
| EBITDA | (1.81B) | (2.06B) | (821.29M) | (484.39M) | (254.61M) |
| EBITDA Margin | -575.7% | -431.2% | -326.6% | -213.3% | -149.6% |
| Operating Income | (1.83B) | (2.21B) | (864.41M) | (559.76M) | (315.28M) |
| Operating Margin | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Interest Income | 837K | 20.26M | 57.22M | 38.61M | 22.62M |
| Interest Expense | 2.37M | 106K | 93K | 94K | 0 |
| Other Income / Expenses | (9.66M) | 87.55M | (28.53M) | 12.25M | 1.68M |
| Income Before Tax | (1.84B) | (2.12B) | (892.94M) | (547.51M) | (313.6M) |
| Pre-Tax Margin | -585.7% | -444.1% | -355.1% | -241.1% | -184.3% |
| Income Tax Expense | (1.48M) | (15.03M) | (71K) | (479K) | (837K) |
| Net Income | (1.83B) | (2.1B) | (892.87M) | (547.03M) | (312.76M) |
| Net Margin | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
| EPS (Basic) | (53.83) | (50.15) | (18.37) | (10.54) | (5.64) |
| EPS (Diluted) | (55.53) | (50.20) | (18.40) | (10.54) | (5.64) |
| Weighted Avg Shares | 32.95M | 41.93M | 48.53M | 51.89M | 55.46M |
| Weighted Avg Shares (Diluted) | 34.01M | 42M | 48.61M | 51.89M | 55.46M |
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.